VEGFC and lymphedema: Finally, rapamycin, an mTOR inhibitor and clinically approved IL-2-dependent immunosuppressant, reversed VEGF-C-induced lymphangiectasia,102 potentially linking lymphedema-related abnormalities with systemic immunity.